[go: up one dir, main page]

BRPI0810365A2 - Inibidores de mlc-1 de indol 7-substituído - Google Patents

Inibidores de mlc-1 de indol 7-substituído

Info

Publication number
BRPI0810365A2
BRPI0810365A2 BRPI0810365-8A2A BRPI0810365A BRPI0810365A2 BR PI0810365 A2 BRPI0810365 A2 BR PI0810365A2 BR PI0810365 A BRPI0810365 A BR PI0810365A BR PI0810365 A2 BRPI0810365 A2 BR PI0810365A2
Authority
BR
Brazil
Prior art keywords
mlc
indol
inhibitors
replaced
replaced mlc
Prior art date
Application number
BRPI0810365-8A2A
Other languages
English (en)
Inventor
Steven W Elmore
Andrew J Souers
Milan Bruncko
Xiaohong Song
Xilu Wang
Lisa A Hasvold
Le Wang
Aaron R Kunzer
Cheol-Min Park
Michael D Wendt
Zhi-Fu Tao
David Madar
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0810365A2 publication Critical patent/BRPI0810365A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0810365-8A2A 2007-04-16 2008-04-16 Inibidores de mlc-1 de indol 7-substituído BRPI0810365A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91203807P 2007-04-16 2007-04-16
US94965007P 2007-07-13 2007-07-13
PCT/US2008/060472 WO2008131000A2 (en) 2007-04-16 2008-04-16 7-substituted indole mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0810365A2 true BRPI0810365A2 (pt) 2014-10-29

Family

ID=39791546

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810365-8A2A BRPI0810365A2 (pt) 2007-04-16 2008-04-16 Inibidores de mlc-1 de indol 7-substituído

Country Status (18)

Country Link
US (3) US8445679B2 (pt)
EP (2) EP3243814B1 (pt)
JP (2) JP5496877B2 (pt)
KR (1) KR101511074B1 (pt)
CN (1) CN101743224A (pt)
AU (1) AU2008242983B2 (pt)
BR (1) BRPI0810365A2 (pt)
CA (1) CA2682356C (pt)
CO (1) CO6220947A2 (pt)
CR (1) CR11107A (pt)
DO (1) DOP2009000246A (pt)
ES (2) ES2643164T3 (pt)
IL (1) IL201432A0 (pt)
MX (1) MX2009011211A (pt)
MY (1) MY162157A (pt)
NZ (1) NZ579833A (pt)
WO (1) WO2008131000A2 (pt)
ZA (1) ZA200906956B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2134685T3 (pl) 2007-04-16 2016-02-29 Abbvie Inc Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
CA2682356C (en) * 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
WO2009143578A1 (en) * 2008-05-28 2009-12-03 The Council Of The Queensland Institute Of Medical Research Cancer drug target and methods of diagnosis and therapy
US8232273B2 (en) * 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
CA2747161C (en) * 2008-12-19 2017-07-18 Abbott Laboratories (hetero)aryl substituted (benzo[d]thiazol-2-ylcarbamoyl) 1,2,3,4-tetrahydroquinolins and related compounds and uses thereof for treating cancer and excess platelets
AU2011210567B2 (en) * 2010-01-29 2015-04-16 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2013235425B2 (en) * 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
EP2831067B1 (en) * 2012-03-29 2017-11-01 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
JP6457942B2 (ja) * 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
WO2014179734A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of Michigan Deuterated amlexanox
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
AU2015235944B2 (en) * 2014-03-27 2020-06-25 Vanderbilt University Substituted indole Mcl-1 inhibitors
EP3125884B1 (en) 2014-04-04 2019-11-06 The Regents of the University of Michigan Small molecule inhibitors of mcl-1 and uses thereof
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
EP3212202B1 (en) 2014-10-29 2020-05-06 The Walter and Eliza Hall Institute of Medical Research Mcl-1 inhibitors for use in treating diseases caused by pathological neovascularisation
CN104557665B (zh) * 2015-01-09 2016-11-30 华东师范大学 光学活性3-取代吲哚衍生物及其合成方法和应用
EP3280708B1 (en) 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
IL259051B2 (en) * 2015-11-02 2024-11-01 Carmel Haifa Univ Economic Corporation Ltd Compounds that mimic APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS), preparations containing them, methods and their uses in initiating differentiation and/or apoptosis in pre-malignant and malignant cells, and restoring their normal-like phenotype
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
GB201521059D0 (en) * 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
EP3407974A4 (en) 2016-01-29 2019-08-28 The Regents Of The University Of Michigan Amlexanox Analogs
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
KR101885084B1 (ko) 2016-03-24 2018-08-03 기초과학연구원 N-아실 인돌 유도체의 아민화 방법
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
MA44721B1 (fr) * 2016-04-22 2020-05-29 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
EP3458459B1 (en) * 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
US11364248B2 (en) 2017-08-18 2022-06-21 Amgen Inc. Compounds that inhibit Mcl-1 protein
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
UY37972A (es) 2017-11-17 2019-06-28 Bayer Pharma AG Derivados de indol macrocíclicos sustituidos con cloro
US11447504B2 (en) 2017-11-17 2022-09-20 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
MA54985A (fr) 2018-03-05 2021-12-29 Amgen Inc Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
WO2020063792A1 (zh) * 2018-09-30 2020-04-02 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
EP3781575A4 (en) 2019-01-23 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. MACROCYCLIC FUSION PYRRAZOLES USED AS MCL-1 INHIBITORS
WO2020221272A1 (zh) * 2019-04-30 2020-11-05 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
US12338250B2 (en) 2019-05-17 2025-06-24 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
CN114269730A (zh) * 2019-08-06 2022-04-01 多曼治疗学公司 作为神经肽ff受体拮抗剂的5-杂芳基-吡啶-2-胺化合物
EP4061820A1 (en) 2019-11-21 2022-09-28 Janssen Pharmaceutica NV Macrocyclic sulfonyl derivatives as mcl-1 inhibitors
CN114728985A (zh) 2019-11-21 2022-07-08 詹森药业有限公司 作为mcl-1抑制剂的大环吲哚衍生物
CN112898224B (zh) * 2019-12-04 2023-02-17 中国科学院上海药物研究所 一种烯丙基醇支撑的大环内酯化合物及其用途
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
CA3178283A1 (en) 2020-05-29 2021-12-02 Frederik Jan Rita Rombouts Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
MX2022015998A (es) * 2020-06-19 2023-04-12 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.
US20230234969A1 (en) 2020-06-19 2023-07-27 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibiors of mcl-1
WO2022255888A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN120641411A (zh) * 2022-12-06 2025-09-12 凯普托尔治疗学股份有限公司 使用结合泛素连接酶和靶mcl-1蛋白的双功能化合物的靶向蛋白降解
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888426A (en) * 1957-08-02 1962-01-31 Lab Francais Chimiotherapie Tryptamine-2-carboxylic acid derivatives and their preparation
US3303195A (en) * 1957-10-31 1967-02-07 Roussel Uclaf Methylated deserpidine
US3578669A (en) 1969-09-16 1971-05-11 Sterling Drug Inc 1-((2 - substituted - 3 - indolyl) - lower-alkanoyl) - cycloalkyl - lower-alkylpiperidines and 1 - ((2 - hydroxymethyl-3 - indolyl)-lower-alkayl)-cycloalkyl-lower-alkylpiperidines
AR205437A1 (es) * 1972-09-25 1976-05-07 Hoffmann La Roche Procedimiento para la preparacion de derivados de indoloquinolinona
US4014883A (en) 1973-09-10 1977-03-29 Hoffmann-La Roche Inc. Indoloquinolines, intermediates and processes
ZA88498B (en) 1987-02-02 1989-10-25 Lilly Co Eli Alkylmelatonins
CS270491B1 (cs) * 1988-10-20 1990-06-13 Magdalena Ing Stankova Způsob výroby kyseliny 7-ethyl-2-karboxyindol- -3—yloclové
FR2662713B1 (fr) 1990-05-29 1994-04-08 Oreal Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
NZ273073A (en) * 1993-09-10 1996-09-25 Eisai Co Ltd Bicyclic heterocyclic sulphonamide and sulphonic acid ester derivatives and pharmaceutical compositions thereof
EP0791582A4 (en) 1995-08-04 1997-12-10 Otsuka Kagaku Kk DERIVATIVES OF INDOLE-2-CARBOXYLIC ACID ESTERS, AND BACTERICIDES FOR AGRICULTURE AND HORTICULTURE CONTAINING THEM AS ACTIVE INGREDIENTS
US6077812A (en) * 1997-02-26 2000-06-20 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
EP1325008B1 (en) * 2000-07-31 2005-10-05 F. Hoffmann-La Roche Ag Piperazine derivatives
CN1505613A (zh) * 2000-10-10 2004-06-16 ʷ��˿�������ȳ�ķ���޹�˾ 取代的吲哚、含这类吲哚的药物组合物及它们作为PPAR-γ结合剂的用途
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
CA2528626A1 (en) * 2003-07-09 2005-01-20 Biolipox Ab Indoles useful in the treatment of inflammation
SE0302035D0 (sv) 2003-07-09 2003-07-09 Biolipox Ab New compound
RS53109B (sr) * 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
ES2365223T3 (es) * 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
ES2395929T3 (es) * 2005-02-25 2013-02-18 Ono Pharmaceutical Co., Ltd. Compuestos de indol para tratar trastornos respiratorios
US8957070B2 (en) * 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP4415896B2 (ja) * 2005-04-20 2010-02-17 トヨタ自動車株式会社 車両用空調装置
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
MX2007016070A (es) * 2005-07-07 2008-03-10 Abbott Lab Promotores de apoptosis.
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
NZ576570A (en) * 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
CA2682356C (en) 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
PL2134685T3 (pl) 2007-04-16 2016-02-29 Abbvie Inc Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1

Also Published As

Publication number Publication date
NZ579833A (en) 2012-11-30
CN101743224A (zh) 2010-06-16
US8445679B2 (en) 2013-05-21
US20090054402A1 (en) 2009-02-26
CR11107A (es) 2010-02-09
EP3243814A1 (en) 2017-11-15
DOP2009000246A (es) 2009-11-15
JP2014129399A (ja) 2014-07-10
IL201432A0 (en) 2010-05-31
MY162157A (en) 2017-05-31
CO6220947A2 (es) 2010-11-19
US9035047B2 (en) 2015-05-19
WO2008131000A2 (en) 2008-10-30
US9359296B2 (en) 2016-06-07
AU2008242983A1 (en) 2008-10-30
WO2008131000A3 (en) 2008-12-18
CA2682356C (en) 2016-06-14
JP5496877B2 (ja) 2014-05-21
CA2682356A1 (en) 2008-10-30
EP2134684B1 (en) 2017-08-02
ES2643164T3 (es) 2017-11-21
US20150284328A1 (en) 2015-10-08
JP2010524956A (ja) 2010-07-22
AU2008242983B2 (en) 2013-07-11
KR101511074B1 (ko) 2015-04-13
ES2705599T3 (es) 2019-03-26
KR20090130137A (ko) 2009-12-17
JP5745661B2 (ja) 2015-07-08
RU2009141986A (ru) 2011-05-27
US20140051683A1 (en) 2014-02-20
MX2009011211A (es) 2009-10-30
ZA200906956B (en) 2011-03-30
EP2134684A2 (en) 2009-12-23
EP3243814B1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
CY2017016I2 (el) Αναστολεις πρωτεασωματος
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
EP2170350A4 (en) SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0806898A2 (pt) Inibidores de mek
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0918564A2 (pt) inibidores
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
BRPI0914942A2 (pt) Compostos de oxindol
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0813867A2 (pt) Composições compreendendo inibidores e hidrolase de triptofano.
AT505058A3 (de) Türschliesssystem
BRPI0812994A2 (pt) Microbiocidas
DK2066662T3 (da) Serinhydrolaseinhibitorer
BRPI0809678A2 (pt) Métodos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]